A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis

Completed · Phase 3 · Has a placebo group

Conditions studied: Allergic Conjunctivitis

In brief

The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.

Key facts

Study ID

NCT04050865

Run by

Ocular Therapeutix, Inc.

People needed

96

Starts

2019-08-05

Expected to finish

2020-02-28

Last updated by the study team

2021-10-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has a positive history of ocular allergies and a positive skin test reaction to a perennial allergen and a seasonal allergen
• Has a positive bilateral CAC reaction to a perennial allergen within minutes of instillation

You may not qualify if…

• History of refractive surgery (including LASIK procedures) within the past 2 years
• History of retinal detachment, diabetic retinopathy, or active retinal disease
• Presence of an active ocular infection or positive history of an ocular herpetic infection at any visit
• History of IOP increase as a result of steroid treatment
• A female who is currently pregnant, planning a pregnancy, or lactating

Where it is running

• Vision Institute — Colorado Springs, Colorado, United States
• The Eye Care Institute — Louisville, Kentucky, United States
• Andover Eye Associates — Raynham, Massachusetts, United States
• Silverstein Eye Centers — Kansas City, Missouri, United States
• Total Eye Care, P.A. — Memphis, Tennessee, United States
• Eye Associates of Texas — Round Rock, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.